Caplin Point Laboratories Limited
CAPLIPOINT · General/Diversified · NSE
₹2,309
Current Market Price
Fair Value (DCF)
₹1,188
Discount to FV
-48.6%
Updated just now
YieldIQ Score
37/100
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
61%
ROE
17.9%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹17,554 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
24.4%
Return on capital employed
EV / EBITDA
12.9×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
1110.5×
EBIT covers interest
Current Ratio
6.97×
Short-term liquidity
Asset Turnover
0.66×
Revenue per ₹ of assets
Revenue CAGR (3Y)
6.6%
3-year revenue growth
Revenue CAGR (5Y)
9.9%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,309.4
Bear case
Discount -228.0%
Base case
Discount -94.4%
Bull case
Discount -41.2%
Ratio Trends
CAPLIPOINT · last 10 annual periods
ROE
17.9%
ROCE
24.4%
Operating Margin
—
Debt / Equity
0.00×
PE
17.8×
EV / EBITDA
12.9×
Historical Financials
CAPLIPOINT · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1269 Cr | ₹1454 Cr | ₹1680 Cr | ₹1937 Cr | ₹2187 Cr | +14.6% |
| EBITDA | ₹433 Cr | ₹497 Cr | ₹619 Cr | ₹743 Cr | ₹876 Cr | +19.2% |
| EBIT | ₹387 Cr | ₹452 Cr | ₹565 Cr | — | — | +10.0% |
| PAT | ₹300 Cr | ₹376 Cr | ₹457 Cr | ₹536 Cr | ₹641 Cr | +20.9% |
| EPS (diluted) | ₹39.26 | ₹49.18 | ₹59.90 | — | — | +11.1% |
| CFO | ₹337 Cr | ₹271 Cr | ₹318 Cr | ₹432 Cr | ₹523 Cr | +11.6% |
| CapEx | ₹-91.2 Cr | ₹-193 Cr | ₹-146 Cr | ₹-192 Cr | ₹-248 Cr | — |
| FCF | ₹246 Cr | ₹77.9 Cr | ₹173 Cr | ₹241 Cr | ₹275 Cr | +2.9% |
| Total Assets | ₹1736 Cr | ₹2191 Cr | ₹2698 Cr | ₹3208 Cr | ₹4045 Cr | +23.5% |
| Total Debt | ₹2.1 Cr | ₹5.5 Cr | ₹2.0 Cr | ₹5.0 Cr | ₹4.6 Cr | +21.3% |
| Shareholders' Equity | ₹1484 Cr | ₹1880 Cr | ₹2316 Cr | ₹2850 Cr | ₹3586 Cr | +24.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
CAPLIPOINT vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 JUBLPHARMA JUBLPHARMA | — | — | Pending | 5.6% | 32.5× |
 APLLTD APLLTD | — | — | Pending | 11.9% | 19.3× |
 COHANCE COHANCE | — | — | Pending | 4.6% | — |
 NATCOPHARM NATCOPHARM | — | — | Pending | 15.4% | — |
ALIVUS ALIVUS | — | — | Pending | 16.9% | — |
Click a ticker to view its fair-value analysis.
Dividend History
17 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹25.00/sh
Last payout
2026-05-29
₹4.00
Peak payout
₹4.00
Trailing yield
0.30%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Caplin Point Laboratories Limited (CAPLIPOINT.NS) trades at 2309.40 vs a model fair value of 1187.95, a gap of -48.6%. Piotroski F-score:...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of CAPLIPOINT →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for CAPLIPOINT →
Compare
Head-to-head with peers
Compare CAPLIPOINT side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse CAPLIPOINTNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.